4 minutes to Read

Your patient uses gliclazide and insulin but could still benefit from the additional cardiovascular and renal protections of empagliflozin. How would you manage the change in treatment? 

This case study is particularly relevant to prescribers. It originally appeared in the 3 March 2021 issue of New Zealand Doctor Rata Aotearoa and has been republished with permission.

Contributor
Penny Clark, Dr Linda Bryant
13 April 2021
11 minutes to Read

Current management of type 2 diabetes includes two new classes of medication, SGLT2 inhibitors and GLP-1 receptor agonists, where clinically indicated. This article was published in the April 2021 edition of Kai Tiaki. It has been edited specifically for our nursing readership from an article that appeared in New Zealand Doctor and Pharmacy Today late in 2020. 

This article is endorsed by the College of Nurses Aotearoa (NZ) Inc.

Contributor
Dr Rinki Murphy, Lisa Sparks
9 April 2021
65 minutes to Watch

In this webinar, Dr Ryan Paul discusses the changes to type 2 diabetes care in 2021, including when and how to use SGLT2 inhibitors and GLP-1 agonists. You can watch the webinar here or in ELearning. 

Downloadable empagliflozin patient information and a recent slide presentation can be found within this article.

Contributor
Dr Ryan Paul
4 March 2021

If you're having trouble pronouncing the name of the newly funded SGLT2 inhibitor for type 2 diabetes, you're not the only one! Watch our video guide to learn how to pronounce empagliflozin. 

Contributor
He Ako Hiringa
3 March 2021
10 minutes to Read

Inequities exist in all aspects of diabetes care. In this article, Alesha Smith outlines some examples, proposes some actions, and explains where the new medicines fit in. 

This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 0.5 CME credits for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.

Contributor
Dr Alesha Smith
3 February 2021
1 minute to Read

Late last year, PHARMAC announced the SGLT2 inhibitor empagliflozin (Jardiance®) and empagliflozin with metformin (Jardiamet®) will be funded for the treatment of type 2 diabetes under Special Authority.

Find out all you need to know about the Special Authority criteria. 

Contributor
He Ako Hiringa
25 January 2021